As gene therapy programs move toward commercialization, fragmented data and complex CMC processes can create significant barriers to speed and scalability.
In this article published in Cell & Gene, Viralgen explores how combining a standardized rAAV manufacturing platform with structured digital CMC data can help accelerate technology transfer, streamline onboarding, and reduce manufacturing inefficiencies — highlighting a recent sponsor onboarding that reduced an overall timeline of up to a year to just three months.
Download the full article to learn how structured data can help turn platform capabilities into measurable commercial impact.